Navidea Biopharmaceuticals Inc (NAVB)

[RMD1]

Lymphoseek alone will be the main driver. sNDA's will be issued for the next five years with all the trials they are working on. Then the development of their pipeline for the next three years. This manipulation is temporary. They can't make hundred share trades every hour for the next year. Remember more than likely this is being pushed down by shorts that are taking advantage of the "dilution" story. Anyone selling at today's levels is selling at a loss if they have bought within the last three years. This is not the type of company that will be going bankrupt anytime soon.